Bruce E Lerner, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 8953 Linden Ln, Prairie Village, KS 66207 Phone: 913-707-5294 |
Dr. Cecile Khoury, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 4201 W 90th Ter, Prairie Village, KS 66207 Phone: 913-345-8963 |
News Archive
The COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) has reviewed reports of rare cases of blood clots with low platelets following vaccination with the AstraZeneca COVID-19 vaccine (including Covishield) since their onset a few weeks ago.
Events that take place early in life almost certainly have consequences for later cognitive development. Establishing the connections is difficult, however, because human infants cannot be used as laboratory subjects. Rodney Johnson and his collaborators have developed an alternative model for studying infant brain development. "Assistant professor Ryan Dilger and I became interested in establishing the neonatal piglet as a model of human brain and cognitive development 3 or 4 years ago," he said.
A new research report published in the Journal of Leukocyte Biology shows how the bacteria known for causing gum disease-Porphyromonas gingivalis-manipulates the body's immune system to disable normal processes that would otherwise destroy it. Specifically, the report shows that this pathogen prompts the production of the anti-inflammatory molecule Interleukin-10 (IL-10).
A researcher who is working on a vaccine for Alzheimer's disease (AD) has demonstrated that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer's patients. This continuing research at Ben-Gurion University of the Negev could one day lead to specific Alzheimer's vaccines that reduce plaque, neuronal damage and inflammation associated with the disease.
Inc. magazine ranked Signature Genomic Laboratories no. 1012 on its third annual Inc. 5000, an exclusive ranking of the nation's fastest-growing private companies. The company, which performs microarray-based diagnostic genetic testing of chromosome abnormalities in individuals with unexplained mental retardation and/or birth defects, experienced three-year sales growth of 302.9%, more than twice that of the Inc. 5000 industry median and over 12 times the industry benchmark. Signature was also ranked 70th of companies in the healthcare sector.
› Verified 6 days ago